Skip to content

Attention Bias Modification Versus Attention Control in Treatment of Social Anxiety

Attention Bias Modification Versus Attention Control in Treatment of Social Anxiety

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05018260
Enrollment
50
Registered
2021-08-24
Start date
2021-05-01
Completion date
2022-04-01
Last updated
2023-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Social Anxiety, Social Anxiety Disorder, Social Anxiety Disorder (Social Phobia)

Keywords

social anxiety, social phobia, attention bias modification, attention control

Brief summary

The purpose of this study is to compare the clinical efficacy of treatment using gaze contingent music reward therapy (GC-MRT) with attention control treatment based on a similar paradigm, for social anxiety disorder (SAD)

Detailed description

This study examines the possibility that the effectiveness shown for GC-MRT in the treatment of SAD leans on attention control rather than bias modification. Therefore half of the participants will receive the classic GC-MRT course of treatment while the other half a version of the task with non-emotional stimuli (geometric shapes).

Interventions

BEHAVIORALAttention Bias Modification

Feedback according to participants' viewing patterns, in order to modify their attention bias to threat

BEHAVIORALAttention Control

Feedback according to participants' viewing patterns, in order to strengthen their attention control

Sponsors

Tel Aviv University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

particiapants, investigators and outcome assessors are blind to allocation

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* A signed consent form * Men and women between the ages of 18 and 65. * Meeting a current diagnosis of Social Anxiety Disorder (SP) according to the DSM-IV. * SP as the primary diagnosis: In cases of co-morbidity, SP will be deemed as the most distressing and clinically significant condition among the co-morbid disorders. * No current pharmaco-therapy.

Exclusion criteria

* A diagnosis of psychotic or bipolar disorders. * A diagnosis of a neurological disorder (i.e., epilepsy, brain injury). * Drug or alcohol abuse. * Any current pharmacological treatment. * Any current psychotherapeutic treatment. * Change in treatment during the study. * Poor judgment capacity (i.e., children under 18 and special populations).

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline - the Liebowitz Social Anxiety Scale (LSAS) - Diagnostic Interview scoresat baseline, one week after end of interventionThe Liebowitz Social Anxiety Scale (LSAS) is a 24-item scale, each item corresponding to a situation selected on the basis of clinical experience. Each item is rated on a severity scale ranging from 0 to 3 with regard to the passing week, measuring separately two components of social anxiety, specifically, fear/anxiety and avoidance of social interaction and performance situations. The minimum and maximum values of the LSAS total score are 0 and 144, respectively, with higher scores mean worse outcome. Although the assessor may request and ask for further detail and adjust the rating based on clinical experience, this option is not often exercised, and inter-rater agreement is not considered to be a relevant concern.

Secondary

MeasureTime frameDescription
Change from baseline - the Social Phobia Inventory scoresat baseline, one week after end of interventionThis is a 17-item self-report measure of social anxiety evaluating fear, avoidance and physiological discomfort. Each item is rated on scale ranging from 0 to 4 with a total score ranging from 0 to 68. Higher scores mean worse outcome.
Clinical Global Impressionat baseline, one week after end of interventionA global measure of clinician impression improvement and severity of illness, ranging from 1 to 7. Higher scores mean worse outcome.

Other

MeasureTime frameDescription
Change from baseline -Attention Control Scale- ACSat baseline, one week after end of interventionThe Attention Control Scale (ACS) assesses attention control, using 20 items rated from 1 to 4. The total score ranging from 20 to 80, with higher scores mean better outcome.
reaction times on the Flanker task, representing attention controlat baseline, one week after end of interventionattention control will be measured using the established Flanker test, to assess change from baseline following treatment.
Change from baseline - Patient Health Questionnaire- PHQ9at baseline, one week after end of interventionThe Patient Health Questionnaire (PHQ9) assesses depressive symptoms using a self-report, 9 question questionnaire. Items are rated on a scale of 0-3 representing the frequency of depressive symptoms over the past 2 weeks. Scores range between 0 to 27, with higher scores mean worse outcome.
Viewing patterns on disgusted and neutral faces, and round/sharp shapes< representing attention bias.at baseline, one week after end of interventiongaze patterns measured using an established eye tracking task, measuring dwell time on different types of stimuli within a 4X4 matrix.

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026